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Towards Predictive Oral and Maxillofacial Medicine: Perspective 
on Zavras et al 
The President’s Council of Advisors on Science and Technology 
recently characterized personalized medicine as “the ability to classify 
individuals into subpopulations that differ in their susceptibility to a 
particular disease or their response to a specific treatment. 
Preventive or therapeutic interventions can then be concentrated on 
those who will benefit, sparing expense and side effects for those 
who will not1.” 
Alternatively termed precision medicine, molecular medicine, 
genomic medicine, and prospective medicine, this approach to 
patient care formalizes and fine tunes the long-standing practice in 
the health care field of tailoring a patient’s management, be it in 
adjusting the frequency of preventive screening appointments or in 
the definitive treatment of their disease, to his or her unique set of 
characteristics by incorporating insight obtained from the large 
number of recent advances in genomics, proteomics and molecular 
biology. By stratifying a patient’s disease susceptibility or targeting an 
individual to a specific treatment protocol to increase the likelihood of 
a positive response to therapy, the ultimate objective of personalized 
medicine is improved patient care. The prospect of stratifying patients 
by both disease susceptibility and expected response to therapeutic 
intervention would also be of benefit in identifying therapies that might 
be of potential benefit within subsets of the population having specific 
disease susceptibility markers that might otherwise be statistically 
masked by larger subsets of the population dominated by non-
responders.  
The concept and practice of personalized medicine is no stranger to 
the practicing oral and maxillofacial pathologist, who incorporates 
these principals into clinical practice on a daily basis, whether it be in 
assessing a patient for a possible deficiency of red blood cell 
glucose-6-phosphate dehydrogenase prior to instituting therapy with 
Dapsone for management of the patient with pemphigoid 
unresponsive to first line therapy, performing fluorescent in situ 
hybridization to identify a possible ETV6-NTRK3 gene fusion in order 
to differentiate acinic cell carcinoma from mammary analogue 
secretory carcinoma, or identifying the presence of high risk human 
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papilloma virus (HPV) in oropharyngeal carcinoma by means of in 
situ hybridization and/or immunohistochemistry for the surrogate 
marker p16 in order to predict prognosis and, possibly, guide therapy. 
 
While proteomics will inevitably play an increasingly important role in 
the future of personalized medicine, currently much of the focus in 
this field has been in the area of short nucleotide polymorphisms 
(SNPs). SNPs are single nucleotide variations within the genome that 
are estimated to represent close to 90% of all human genetic 
variation. To date, millions of SNPs have been identified and listed in 
the SNP database2 administered by the National Center for 
Biotechnology Information in collaboration with the National Human 
Genome Research Institute. Although the majority of these SNPs are 
likely to be of no clinical significance, a yet to be determined 
percentage are believed to affect an individuals response to agents 
such as drugs and microbial challenges as well as their predisposition 
to developing specific health conditions.  
 
Within the past 10 years, there has been a near exponential growth in 
the use of genome-wide association (GWA) studies in order to try to 
identify single nucleotide gene sequence variations that may 
predispose individuals to the development of complex, non-single 
gene inherited diseases typified by most types of malignant 
neooplasms. By this approach, large numbers of individuals affected 
by a disease (the case group) and unaffected healthy individuals (the 
control group) are compared for the presence of statistically 
significant differences in the allele frequency of the examined SNPs. 
A commonly used alternative to GWA studies is the hypothesis-driven 
candidate gene study, involving the targeted assessment of one or 
more areas of a specific gene. 
 
In this issue of OOOOE, Zavras and colleagues present preliminary 
data demonstrating a possible association between short nucleotide 
polymorphisms in ERCC5 (“excision repair cross-complementing 
associated rodent repair deficiency, complementation group 5”), an 
enzyme involved in DNA damage repair, and variances in the risk of 
developing squamous cell carcinoma in their patient population. 
Specifically, they demonstrated that homozygosity for a specific 
single nucleotide polymorphism (the C allele at rs751402) in the 
proximal promoter region of ERCC5 is potentially associated with 
lower rates of oral squamous cell carcinoma, whereas rs751402 T 
alleles appeared to be associated with an increased risk.  
 
ERCC5 is one of the main constituents of a group of proteins involved 
in the nucleotide excision repair (NER) pathway, by which smoking-
related DNA adducts, carcinogens covalent bound to DNA, are 
repaired. As unrepaired DNA damage resulting from exposure to 
environmental carcinogens is believed to be an early event in the 
process of carcinogenesis, there is strong biologic plausibility for the 
hypothesis that an individual’s variation in the efficacy of DNA repair 
activity could have an association with differences in the risk of 
carcinogenesis. There is additional corollary data that would appear 
to strengthen such an association. For one, it is known that mutations 
in this gene cause one subtype of xeroderma pigmentosum, a 
genodermatosis characterized by increased susceptibility for skin 
cancer development following exposure to ultraviolet light. Looking at 
oral squamous cell carcinoma in particular, there is preliminary 
evidence that polymorphisms in cell cycle control genes may be 
associated with increased oral cancer susceptibility (e.g. CCND1 
gene encoding for protein Cyclin D13). More than 70 non-
synonymous SNPs (i.e. single nucleotide polymorphisms leading to a 
change in protein sequence) have been identified in the coding region 
for ERCC5. As noted by Zhu et al4, several studies have indicated 
that polymorphisms in ERCC5 may be associated with the risk of 
developing breast, lung, bladder, and esophageal cancer. However, 
many of the published hypothesis-driven candidate gene studies 
have provided conflicting results.  A recent meta-analysis5 of 44 
published case-control studies, comprising 23,490 cases and 27,168 
controls looking at the association between another widely studied 
ERCC5 SNP (rs17655) and overall cancer risk, concluded that it was 
unlikely that this specific polymorphism contributes to increased 
susceptibility to cancer risk. 
 
The results of this preliminary hospital-based case control 
hypothesis-driven candidate gene study are of obvious interest to the 
readers of OOOO. Nevertheless, without diminishing the findings 
from this study, it is important to point out that thousands of potential 
SNP-disease predisposition associations have been identified, with 
many more characterized on a daily basis. The larger impact of this 
study lies in the fact, by building upon a larger body of existing data, it 
highlights the progress that has been made, and the challenges 
ahead, in moving towards the goal of predicting individual disease 
risk.  
 
The authors acknowledge a number of limitations in their study. 
Women were under-represented relative to the general population in 
the control group (25%) as well as in the case group (3.7% female). 
Information on smoking, alcohol, and areca nut use was collected in a 
binary “current user” or “nonuser” form, without stratifying individuals 
based on duration or lifetime quantity of consumption. There were 
also marked differences in identifiable risk factors between the case 
group and the control group, although the authors did adjust for these 
disparities as part of their statistical analysis. While there are 
accepted differences in the statistical analysis and approaches to 
matching controls in genetic association studies compared to 
conventional case control studies, especially where it comes to 
environmental confounding6, selection of controls for smaller 
candidate gene driven studies should ideally follow classical 
epidemiological control recruitment guidelines, such that the controls 
have the same opportunity to develop the disease as the cases7. 
 
The findings from this study should also not be generalized to other 
populations, because, as necessitated by genetic association case 
control studies such as the current one, the subjects were specifically 
selected to represent a population of genetically similar individuals (in 
this case, from a localized geographic region of Taiwan).  
 
Most significantly, for a case control study, the overall magnitude of 
the effect was relatively small, with an odds ratio of 2.1 for the TT 
homozygotes. When assessing risk susceptibility in conditions with a 
strong environmental component, the strength of the association is of 
particularly significance.  
 
While further validation by larger population-based case-control 
studies is needed, these results, if supported by future studies, raise 
the intriguing prospect of being able to stratify a patient’s risk of oral 
cancer susceptibility, thereby potentially guiding prevention strategies.  
 
This component of personalized medicine, better termed predictive 
risk testing, predictive medicine, or, when focusing on the field of oral 
pathology, “predictive oral and maxillofacial medicine”. 
 
A number of issues must be addressed before this approach can be 
introduced into clinical practice with any degree of confidence. For 
example, it is clear that lifestyle and environment (e.g. smoking 
history) have a significant influence on the development of many 
conditions that affect the oral and maxillofacial region, regardless of 
specific genetic makeup. In many cases, these environmental factors 
may have a more significant effect than specific putative disease 
associated-SNPs. Therefore, in order to have a meaningful clinical 
impact, this type of approach should identify individuals with a 
substantially elevated risk of developing the condition in question. 
Ultimately, in order to increase predictive power, panels of highly 
individualized and statistically validated predisposition SNPs will need 
to be developed (e.g. an oral cancer risk factor SNP panel).   
 
In order to justify undergoing testing, and the associated potential 
psychological considerations associated with both true-positive and 
false positive results, there must also be an appropriate intervention 
that would ultimately reduce or counterbalance a patient’s inherent 
increased risk.  
 
Looking at the potential introduction of a single SNP-based predictive 
test (e.g. rs751402 for the assessment of oral cancer risk), the 
obvious issue would be to determine to whom this test would be 
targeted: the patient at higher risk for oral cancer due to a long history 
of cigarette and alcohol consumption, the patient with a clinically 
diagnosed leukoplakia, or the individual with mild dysplasia? In this 
scenario, it could be argued that the clinician’s efforts and the 
additional health care costs involved in performing this test could be 
put to better use encouraging changes in high risk behavioral 
patterns. On the other side of the equation, one can’t help but wonder 
what effect a test result suggesting a decreased risk of developing 
the condition in question e.g. oral cancer, might have on the patient’s 
health behavior? Would this potentially encourage the individual to 
continue with their smoking habit, under the false reassurance that 
they are “low risk”?  
 
The above noted concerns regarding the applicability of predictive 
risk testing based on analysis of a single SNP become less of a 
concern, of course, as the field transitions to the use of panels 
employing hundreds of thousands to millions of validated SNPs 
encompassing a myriad of conditions. A number of these panel-
based predictive risk-testing products, currently analyzing 500,000 to 
a million-plus SNPs, are being marketed directly to consumers (e.g. 
deCODEmeTM,; 23andmeTM), for as low as $300 US per test. For 
approximately $10,000 US, with a physician’s referral, an individual 
can acquire their full genome sequence (e.g. Individual Genome 
SequencingTM, Illumina Inc.). An iPadTM app is even available 
(MyGenome) that permits users to explore which of their genetic 
polymorphisms could potentially predispose to health impacts. For 
those who do not have access to their own genome sequence, the 
genome of the Illumina CEO is preloaded in the app! 
 
From a regulatory point of view, despite an explosion in the number 
of potential markers, oversight into the validity of these tests has 
been varied. In an investigation by the United States Government 
Accountability Office (GAO)8, differing disease risk predictions were 
received from four different direct to consumer (DTC) genetic testing 
companies using identical DNA samples. Those predictions often 
conflicted with the donor’s previously diagnosed medical conditions 
and/or family history. In contradiction to the GAO’s findings, a 
separate peer-reviewed study published in Clinical Chemistry9 
reported a greater than 99.6% concordance in SNP analyses 
obtained from four different DTC tests, but did note disparities in the 
supplied risk estimates, which the authors attributed to differences in 
the SNPs analyzed as well as the reference populations used in the 
different companies’ calculations. The latter observation reflects the 
fact that much of the underlying risk data in both genome-wide 
association and hypothesis-driven candidate gene studies are 
derived from Caucasian populations, rendering the validity of 
extrapolating these associations to non-Caucasian populations 
unclear.  
As noted by Hamburg and Collins10, while a multitude of genetic 
variations have been identified that can both predispose to the 
development of disease and predict a patient’s response to therapy, 
the challenge remains that of incorporating this knowledge into 
routine patient care. Currently, gene-based predictive risk testing has 
important limitations, in part because single SNPs for complex 
conditions such as oral squamous cell carcinoma do not entirely 
predict outcomes, in part by failing to account for environmental 
influences. High-level analysis of very large population-based data 
will be required before this approach can be widely accepted for 
clinical use. However, there should be no doubt that, in a relatively 
short period of time, as our knowledge base in this area continues to 
expand at an exponential rate, predictive risk testing will have a major 
impact on the practice of oral and maxillofacial pathology.  
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